Synexus and US based Radiant Research today announced their full operational integration to create the world’s largest site network for clinical trials and research.
The company, operating under the Synexus name, will be market leader in the site network space, running 185 sites across 11 countries and offering access to over 100 million patients in key clinical development markets.
The collaboration provides a strong strategic fit for the European headquartered Synexus and Radiant Research which has over 75 sites across the US. Together both companies randomised over 10,500 patients in 2016.
The move provides biopharmaceutical and contract research organisation (CRO) customers with an unmatched opportunity to find the right patient for the right trial at the right time across US, Europe and South Africa. One aim is to harness this new unparalleled Synexus network to sign customer contracts for integrated multi-site trials across the world.
Christophe Berthoux, who has served as Chief Executive Officer for Synexus since 2010 will lead the new organisation formed by the integration of the two companies. He said: “We are delighted to be working together with the Radiant team. Best practices from Synexus, Radiant and our earlier acquisition of Research Across America will be incorporated across our global network of sites.”
He elaborated: “Our integrated commercial approach benefits our customers with a single site network solution, reduced timelines, improved efficiencies, faster activation, and better predictability in enrollment. We are excited to move forward under the name of Synexus and as the world’s leading site network.”
Mike Clay will lead the US operations of the combined business, reporting directly to Berthoux. “Our strategy for seamless integration will ensure excellence in customer service as we transition to a broader, global capability for our customers,” Clay said.
For more information, please visit www.radiantresearch.com